Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics (NASDAQ: NBRV) has priced its public offering of 6,000,000 ordinary shares at $2.50 each, aiming to raise $15 million in gross proceeds. The offering is set to close around December 15, 2020, pending customary closing conditions. H.C. Wainwright & Co. is the exclusive placement agent, with Northland Securities serving as a financial advisor. This offering follows a shelf registration statement filed with the SEC on September 11, 2020. Nabriva focuses on developing innovative anti-infective agents, including FDA-approved XENLETA® and the potential epoxide antibiotic CONTEPO™.

Nabriva Therapeutics plc (NASDAQ: NBRV) has commenced a public offering of its ordinary shares, or pre-funded warrants. The offering will be conducted by Nabriva Therapeutics and is subject to market conditions. There is no assurance regarding the completion or specific terms of the offering. H.C. Wainwright & Co. is the exclusive placement agent for this offering, which will utilize a shelf registration statement filed with the SEC. This announcement does not constitute an offer to sell or solicitation to buy securities in jurisdictions where prohibited.

Nabriva Therapeutics has restructured its license agreement with Sinovant Sciences for XENLETA in greater China, enhancing manufacturing collaboration and regulatory support. The agreement accelerates milestone payments, including a $1 million payment in Q4 2020, part of a potential $5 million total for regulatory approvals. Nabriva originally licensed XENLETA to Sinovant in 2018, with potential additional payments of up to $90 million and royalties on sales post-approval. XENLETA is designed to treat community-acquired bacterial pneumonia.

Nabriva Therapeutics (NASDAQ: NBRV) announced a 1-for-10 reverse stock split effective December 3, 2020, to comply with Nasdaq's minimum $1.00 per share requirement. This consolidation will reduce the outstanding shares from approximately 150.8 million to 15.08 million and adjust the authorized shares from 1 billion to 100 million. No fractional shares will be issued; instead, shareholders will receive cash for any fractional amounts. The move aims to maintain compliance with Nasdaq listing standards.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company focused on anti-infective agents, announced participation in two upcoming investor conferences in November 2020. Management will host investor meetings at the Jefferies Virtual London Healthcare Conference on November 17-18 and at A.G.P.'s Virtual Healthcare Symposium on November 19. Nabriva has developed XENLETA, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, and is advancing CONTEPO for complicated urinary tract infections.

Nabriva Therapeutics plc (NASDAQ: NBRV) announced a significant decrease in its financial performance for Q3 2020, with revenues dropping from $6.9 million in 2019 to $1.3 million this year. This decline was driven by reduced collaboration and product revenues. The company relaunched its products, Xenleta and Sivextro, with plans to expand its sales force. Additionally, they engaged in a Type A meeting with the FDA regarding the Contepo NDA, awaiting further inspection guidelines. As of September 30, 2020, cash reserves stood at $41.1 million.

Nabriva Therapeutics (NASDAQ: NBRV) will report its third-quarter financial results on November 5, 2020, post U.S. market close. A conference call is set for 4:30 p.m. ET to discuss results and corporate highlights. The company focuses on developing innovative anti-infective agents like XENLETA and Contepo, with XENLETA already FDA-approved for pneumonia. Nabriva has partnered with Merck & Co. for distributing SIVEXTRO in the U.S.

Nabriva Therapeutics (NASDAQ: NBRV) announces promising results for XENLETA™ (lefamulin), a pleuromutilin antibiotic, from a pooled analysis of Phase 3 LEAP 1 and LEAP 2 trials. Conducted on 1,289 patients, the analysis shows that XENLETA is effective and safe in treating community-acquired bacterial pneumonia (CABP) in older patients with comorbidities. Approximately 40% of patients were over 65, indicating a high response rate of around 90%, comparable to moxifloxacin. Results will be presented at the CHEST Annual Meeting from October 18-21, 2020.

Nabriva Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for XENLETA (lefamulin) and CONTEPO (fosfomycin). Effective October 1, 2020, XENLETA will receive an additional $1,275.75 for inpatient use. Additionally, CONTEPO is the first Qualified Infectious Disease Product to receive conditional NTAP prior to FDA approval, with a potential maximum payment of $2,343.75. These developments aim to enhance hospital access to innovative antibiotics, responding to the critical need for new anti-infective treatments.